Filing Details

Accession Number:
0001711279-23-000023
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-04-21 16:10:57
Reporting Period:
2023-04-19
Accepted Time:
2023-04-21 16:10:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1711279 Krystal Biotech Inc. KRYS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1198325 Daniel Janney C/O Krystal Biotech, Inc.
2100 Wharton Street, Suite 701
Pittsburgh PA 15203
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-04-19 7,900 $90.32 224,462 No 4 S Indirect Directly beneficially owned by Alta Bioequities, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Directly beneficially owned by Alta Bioequities, L.P.
Footnotes
  1. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2022 and will terminate on September 11, 2023 and contemplates sales of 25,000 shares with a limit price of $90.00 per share.
  2. The transaction was executed in multiple trades ranging from $90.0000 to $90.3650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
  3. Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.